The MEK inhibitor G-38963, along with anti-PD-L1 therapy promotes effector function and lifespan of tumor-infiltrating CD8+ T-cells leading to synergistic inhibition in tumor growth [40]. This evidence concerns the gene CD8A and neoplasm.